Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. Issue 14 (6th December 2022)

• Record Type: Journal Article
• Authors: Shahzad, Moazzam; Tariq, Ezza; Chaudhary, Sibgha Gull; Anwar, Iqra; Iqbal, Qamar; Fatima, Huda; Abdelhakim, Haitham; Ahmed, Nausheen; Balusu, Ramesh; Hematti, Peiman; Singh, Anurag K.; McGuirk, Joseph P.; Mushtaq, Muhammad Umair
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 14(2022)
• Page Start: 3409
• Page End: 3417
• Publication Date: 2022-12-06
• Subjects: Acute myeloid leukemia -- TP53 mutation -- allogeneic hematopoietic stem cell transplantation -- outcomes; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2123228
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) in TP53-mutated acute myeloid leukemia (AML). We performed a literature search on PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. After screening 592 manuscripts, eight studies were included. Data were extracted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Pooled analysis was done using the meta-package by Schwarzer et al. Proportions with 95% confidence intervals (CIs) were computed. We analyzed 297 patients. The median follow-up was 45 (0.9–407.3) months. The pooled 2-year overall survival was 29.7% (95% CI 0.17–0.43, n = 82/248). The pooled relapse rate was 61.4% (95% CI 0.41–0.79, n = 139/247) at a median follow-up time of 2 (0.26–3) years. Three-year progression-free survival and non-relapse mortality were reported by one study as 7.5% and 32.5%, respectively. Outcomes of HSCT for TP53-mutated AML are poor; however, HSCT confers a survival advantage as compared to non-transplant palliative therapies.